CTOs on the Move

Intra-Cellular Therapies

www.intracellulartherapies.com

 
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Mallinckrodt

At Mallinckrodt, we use strategic vision and employee-driven momentum to pursue a powerful mission: Managing Complexity. Improving Lives. As a specialty pharmaceuticals leader, we develop, manufacture, market and distribute specialty pharmaceuticals and therapies. Within our areas of focus, we provide treatments to underserved patient populations within neurology, rheumatology, nephrology, pulmonology, and ophthalmology. At Mallinckrodt, we use strategic vision and employee-driven momentum to pursue a powerful mission: Managing Complexity. Improving Lives. As a specialty pharmaceuticals leader, we develop, manufacture, market and distribute specialty pharmaceuticals and therapies. Within our areas of focus, we provide treatments to underserved patient populations within neurology, rheumatology, nephrology, pulmonology, and ophthalmology. Our expertise also extends into acute and critical care hospital products, as well as our broad portfolio of generic prescription medicines, and active pharmaceutical ingredients. Together, we`re helping shape the future of the specialty pharmaceuticals industry by leveraging the values our founders instilled nearly 150 years ago – quality, integrity and service. Mallinckrodt Pharmaceuticals provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, gender identity, national origin, age, disability, veteran status, or genetics. In addition to federal law requirements, Mallinckrodt Pharmaceuticals complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation and training.

Windtree Therapeutics

Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee`s HK, while Windtree evaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults. Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

Fuse Medical

Fuse Medical, Inc., formerly Golf Rounds.com, Inc., is engaged in marketing, distributing and selling internal fixation, bone materials, biologics, tissues, surgical and other related surgical products. The Company operates through medical products and...

Stevanato Group

Founded in 1949, Stevanato Group is committed to create systems, processes and services that guarantee the integrity of parenteral medicines. It is comprised of two operational divisions: Pharmaceutical Systems (Ompi and Balda brands): specialized in ready-to-use glass containers and bulk primary packaging (syringes, cartridges, vials, and ampoules); high quality and high precision plastic solutions for diagnostic, pharmaceutical and medical device applications. Engineering Systems (Spami, Optrel, InnoScan and SVM brands): specialized in glass forming technology, inspection systems, assembly, packaging machines and serialization solutions for the pharmaceutical industry. These two divisions enjoy a close, synchronous relationship, featuring daily exchanges which ensure that Stevanato Group has complete control over the entire production process, from purchasing the finest raw materials to offering exceptional after-sales customer service. The Group also benefits from the SG Lab activity that provides technical and analytical services on the potential interaction between the pharmaceutical product and the container.

Prescription Corporation of America

Prescription Corporation of America is a Denville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.